Profile data is unavailable for this security.
About the company
Thiogenesis Therapeutics, Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is developing sulfur-containing prodrugs that act as precursors with the potential to treat serious pediatric diseases with unmet medical needs. The Company’s lead compound, TTI-0102, is a disulfide, made up of two thiols that lead to two independent cysteamine molecules. Cysteamine is a thiol that has been rigorously studied and tested. It is the active ingredient used in drugs to treat the lysosomal storage disease - (nephropathic) cystinosis. TTI-0102 has been developed to address the obstacles facing thiol-based drugs, their short half-life, gastrointestinal (GI) side effects and dosing limitations. As a prodrug, TTI-0102 is metabolized into cysteamine molecules after it is ingested. The metabolic process acts as a gating mechanism. TTI-0102’s initial applications are for MELAS, Leigh syndrome, Rett syndrome and pediatric non-alcoholic steatohepatitis (NASH).
- Revenue in CAD (TTM)0.00
- Net income in CAD-4.49m
- Incorporated2018
- Employees--
- LocationThiogenesis Therapeutics Corp4 King Street West, Suite 401Toronto M5H 1B6CanadaCAN
- Phone+1 (647) 846-7766
- Websitehttps://www.thiogenesis.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Resverlogix Corp | 0.00 | -14.72m | 18.13m | 18.00 | -- | -- | -- | -- | -0.0565 | -0.0565 | 0.00 | -0.3845 | 0.00 | -- | -- | 0.00 | -138.80 | -- | -- | -- | -- | -- | -- | -- | 0.0459 | -0.8227 | -- | -- | -- | -- | -363.74 | -- | -- | -- |
COSCIENS Biopharma Inc | 6.19m | -17.28m | 19.04m | 21.00 | -- | 0.4385 | -- | 3.07 | -12.83 | -12.83 | 3.66 | 11.74 | 0.0936 | 1.74 | 6.35 | -- | -26.11 | -26.24 | -30.53 | -30.34 | 39.42 | 83.68 | -278.95 | -300.31 | 3.05 | -- | 0.0604 | -- | -20.25 | -30.06 | 27.17 | -- | 16.12 | -- |
Sirona Biochem Corp | -16.37k | -2.67m | 19.50m | -- | -- | -- | -- | -- | -0.0105 | -0.0105 | -0.00006 | -0.0134 | -0.0171 | -- | 1.61 | -- | -278.90 | -173.09 | -- | -383.49 | -- | -- | -- | -1,405.28 | -- | -5.73 | -- | -- | -94.82 | -51.37 | 28.52 | -- | -- | -- |
Thiogenesis Therapeutics Corp | 0.00 | -4.49m | 30.62m | -- | -- | 6.41 | -- | -- | -0.1092 | -0.1092 | 0.00 | 0.1045 | 0.00 | -- | -- | -- | -91.94 | -- | -98.58 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- |
Avicanna Inc | 24.87m | -7.44m | 35.98m | 38.00 | -- | 996.92 | -- | 1.45 | -0.0804 | -0.0804 | 0.2714 | 0.0003 | 1.20 | 2.95 | 9.32 | 654,600.00 | -35.85 | -67.17 | -267.70 | -167.73 | 48.66 | 46.36 | -29.90 | -368.82 | 0.3316 | -8.88 | 0.1645 | -- | 314.82 | 169.57 | 40.67 | -- | -32.29 | -- |
Nurexone Biologic Inc | 0.00 | -5.68m | 38.02m | 8.00 | -- | 10.65 | -- | -- | -0.1093 | -0.1093 | 0.00 | 0.0526 | 0.00 | -- | -- | -- | -183.97 | -213.78 | -235.34 | -596.97 | -- | -- | -- | -- | -- | -187.27 | 0.0096 | -- | -- | -- | 55.45 | -- | -- | -- |